Regulus Soars As AstraZeneca Grabs NASH Drug Rights

By | April 7, 2015

Scalper1 News

Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making investments to get part of NASH, a form of liver damage caused by accumulation of fat. Regulus said RG-125, a compound to treat nonalcoholic steatohepatitis (NASH) in patients with type II diabetes or Scalper1 News

Scalper1 News